论文部分内容阅读
目的比较含奈达铂(nedaplatin,NDP)方案化疗联合放疗与单纯放疗对中晚期食管癌的疗效。方法将32例中晚期食管癌患者随机分为联合组和单放组各16例。两组患者均为常规分割放疗,总剂量66~70Gy。联合组在放疗同时使用NDP80mg/m2,d1;5-FU350mg/m2,d1~d5,每28d重复。2个化疗周期后2组同时评价疗效及分析1年生存率。结果联合组与单放组总有效率(CR+PR)分别为81%(13/16)和44%(7/16),两组比较差异有统计学意义,χ2=4.45,P=0.04。联合组与单放组1年生存率分别为81%(13/16)和75%(12/16),两组比较差异无统计学意义,χ2=0.24,P=0.31。Ⅲ度放射性食管炎发生率联合组为37.5%(6/16),明显高于单放组的6.3%(1/16),χ2=5.24,P=0.03。结论含NDP方案化疗联合放疗对中晚期食管癌治疗有协同作用,值得临床进一步研究。
Objective To compare the efficacy of nedaplatin (NDP) chemotherapy with radiotherapy and radiotherapy on advanced esophageal cancer. Methods 32 patients with advanced esophageal cancer were randomly divided into the combined group and the single release group of 16 cases. The two groups of patients were routinely divided radiotherapy, the total dose of 66 ~ 70Gy. Radiotherapy combined with NDP80mg / m2, d1; 5-FU350mg / m2, d1 ~ d5, repeated every 28d. After 2 cycles of chemotherapy, the two groups evaluated the efficacy and analyzed the 1-year survival rate. Results The total effective rate (CR + PR) in combined group and single group was 81% (13/16) and 44% (7/16), respectively. There was significant difference between the two groups (χ2 = 4.45, P = 0.04). The 1-year survival rates were 81% (13/16) and 75% (12/16) in the combined group and the single group, respectively. There was no significant difference between the two groups (χ2 = 0.24, P = 0.31). The incidence of Ⅲ degree radiation esophagitis was 37.5% (6/16) in the combined group, which was significantly higher than 6.3% (1/16) in the radiotherapy group, χ2 = 5.24, P = 0.03. Conclusion NDP regimen combined with radiotherapy has a synergistic effect on the treatment of advanced esophageal cancer, which is worth further clinical study.